{"id":634528,"date":"2023-01-18T16:28:02","date_gmt":"2023-01-18T16:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634528"},"modified":"2023-01-18T16:28:02","modified_gmt":"2023-01-18T16:28:02","slug":"dermatomyositis-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dermatomyositis-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634528.html","title":{"rendered":"Dermatomyositis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1674019265.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dermatomyositis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1674019265.jpeg\" alt=\"Dermatomyositis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Dermatomyositis Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">United States, Nevada, Las Vegas, DelveInsight\u2019s &#8216;Dermatomyositis Pipeline Insight 2023&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dermatomyositis pipeline domain.<\/div>\n<p style=\"text-align: justify;\">United States, Nevada, Las Vegas, DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Dermatomyositis Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dermatomyositis pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dermatomyositis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Dermatomyositis Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 10+ Dermatomyositis pipeline therapies are in various stages of development, and their anticipated acceptance in the Dermatomyositis market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Dermatomyositis companies developing novel drug candidates to improve the Dermatomyositis treatment landscape include<strong> Corbus Pharmaceuticals, Kezar Life Sciences, <\/strong>and others.<\/li>\n<li>Promising Dermatomyositis pipeline therapies in various stages of development include<strong> Lenabasum, KZR-616, <\/strong>and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Dermatomyositis is a type of inflammatory myopathy characterized by inflammatory and degenerative changes of the muscles and skin. Associated symptoms and physical findings may vary widely from case to case as patients may present differently. Muscle abnormalities may begin with aches and weakness of the muscles of the trunk, upper arms, hips, and thighs (proximal muscles). Muscles may be stiff, sore, tender and, eventually, show signs of degeneration (atrophy). Dermatomyositis may be diagnosed based upon a detailed patient history, thorough clinical examination, detection of characteristic physical findings, and certain specialized tests. Glucocorticoids, particularly prednisone, are widely used in treating dermatomyositis and are often used first-line. High dose glucocorticoid therapy may produce adverse side effects, particularly after prolonged use, such as a decrease in bone density, causing bones to become brittle and weakened (osteoporosis); increasing, &ldquo;superimposed&rdquo; muscle weakness due to effects of the medication (i.e., corticosteroid myopathy); tissue swelling (edema); peptic ulcers; elevated blood pressure; elevated blood sugar levels; weight gain with fat deposits in the abdomen, face, and\/or back of the neck or other findings.<\/p>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Lenabasum: Corbus Pharmaceuticals<\/strong><\/p>\n<p style=\"text-align: justify;\">Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has an acceptable safety and tolerability profiles without evidence of immunosuppression. Lenabasum is currently in phase III stage of development to treat Dermatomyositis.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Dermatomyositis drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Dermatomyositis Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Corbus Pharmaceuticals<\/li>\n<li>Kezar Life Sciences<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Lenabasum<\/li>\n<li>KZR-616<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By development stage<\/strong><\/li>\n<li><strong>By product type<\/strong><\/li>\n<li><strong>By route of administration<\/strong><\/li>\n<li><strong>By molecule type<\/strong><\/li>\n<li><strong>By MOA type&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Dermatomyositis Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Dermatomyositis Companies<\/strong>: Corbus Pharmaceuticals, Kezar Life Sciences, and others<\/li>\n<li><strong>Key Dermatomyositis Pipeline Therapies<\/strong>: Lenabasum, KZR-616, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Dermatomyositis treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><strong>Dermatomyositis Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report to know more about the leading companies working in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dermatomyositis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Dermatomyositis Pipeline Segment<\/a>.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dermatomyositis-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dermatomyositis-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dermatomyositis Pipeline Insights United States, Nevada, Las Vegas, DelveInsight\u2019s &#8216;Dermatomyositis Pipeline Insight 2023&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dermatomyositis-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634528.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-634528","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634528"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634528\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}